Drug Profile
CEVA 101
Alternative Names: Autologous BMMNCs - Cellvation/University of Texas Health Science Center, Houston; Autologous bone marrow mononuclear cells - Cellvation/University of Texas Health Science Center at Houston; Autologous bone marrow-derived stem cells – Cellvation/University of Texas Health Science Center at Houston; CEVA101Latest Information Update: 08 Dec 2022
Price :
$50
*
At a glance
- Originator University of Texas Health Science Center at Houston
- Developer Cellvation; National Institute of Neurological Disorders and Stroke; University of Texas Health Science Center at Houston
- Class Cell therapies; Neuroprotectants
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Brain injuries
Most Recent Events
- 08 Dec 2022 CEVA 101 is still in phase II development in Brain injuries (In adults) in USA (IV) (NCT02525432) (Cellvation pipeline, November 2022)
- 08 Dec 2022 CEVA 101 is still in phase II development in Brain injury (In adolescents, In children) in the US (NCT01851083) (Cellvation pipeline, November 2022)
- 12 Oct 2020 The University of Texas Health Science Center at Houston completes a phase II trial in Traumatic brain injury in the US (NCT01851083)